Who Owns Evotec Company?

Evotec Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Evotec SE?

Understanding Evotec SE's ownership is key to its strategy and governance in biotech. A major step was its NASDAQ listing in November 2021, expanding its investor reach and capital access. Founded in 1993, Evotec SE aimed to accelerate drug discovery and development.

Evotec SE is a global leader in drug discovery and development, collaborating with major pharmaceutical firms and research institutions. As of August 20, 2025, its market capitalization stood at approximately $1.30 billion.

Evotec SE's ownership structure features a substantial free float and significant institutional investors, influencing its decision-making. This analysis explores its ownership evolution, from founders' stakes to current major stakeholders, and examines board influence and recent trends. For a deeper dive into its market environment, consider an Evotec PESTEL Analysis.

Evotec SE, initially founded as Evotec BioSystems GmbH in Hamburg, Germany, in 1993, was established by a notable group of scientists and entrepreneurs. Key figures included Nobel Laureate Professor Manfred Eigen, Dr. Karsten Henco, and Dr. Charles Weissmann, among others. Their shared vision was to advance drug discovery through scientific innovation.

Founding Vision

The founders aimed to revolutionize drug discovery processes. Their mission centered on leveraging scientific excellence to identify and develop highly effective therapeutics.

Initial Funding

Early capital for Evotec was secured through various sources. This included investments from venture capital firms and early-stage investors, crucial for establishing operations and R&D.

Public Offering

Evotec BioSystems transitioned to a publicly traded company in 1999. The listing on the Frankfurt Stock Exchange provided significant capital for growth and enhanced market presence.

Founding Team Expertise

The founding team comprised individuals with deep scientific and entrepreneurial backgrounds. This collective expertise was instrumental in shaping the company's strategic direction.

Early Ownership Details

Specific details regarding the initial equity distribution among founders are not publicly disclosed. However, the collective vision and scientific acumen of the founding group were central to the company's early development.

Company Evolution

The company's journey from its inception as Evotec BioSystems GmbH to its current status as Evotec SE reflects a consistent focus on innovation in drug discovery and development.

The foundational ownership of Evotec was rooted in the collective vision of its scientifically accomplished founders. While precise initial shareholdings are not publicly detailed, the company's early trajectory was significantly influenced by venture capital and angel investors who provided the necessary capital for its nascent research and development endeavors. This early backing was critical in establishing the company's infrastructure and pursuing its innovative approaches to drug discovery, as further detailed in the Brief History of Evotec.

Key Aspects of Early Evotec Ownership

The initial ownership structure of Evotec was characterized by the contributions of its founders and early investors. The company's public listing in 1999 marked a significant shift in its ownership landscape.

• Founders' collective scientific and entrepreneurial expertise guided early strategy.
• Venture capital and early-stage investors provided initial funding.
• The company went public in 1999 on the Frankfurt Stock Exchange.
• This public offering facilitated capital infusion for expansion and increased visibility.

Evotec SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Evotec's journey from its inception to its current standing has been marked by significant shifts in its ownership structure. The company's initial public offering on the Frankfurt Stock Exchange in November 1999 laid the groundwork for its growth. This was further bolstered by its NASDAQ listing in November 2021, which provided substantial capital for expansion and strategic initiatives.

As of July 2025, Evotec SE's ownership landscape is characterized by a substantial free float, estimated at around 75%. The company's shareholder base includes three key entities holding more than 5% of its shares: Novo Holdings A/S, Mubadala Investment Company, and Triton GP HoldCo SARL. These major shareholders, alongside a growing presence of institutional investors, play a crucial role in shaping Evotec's strategic direction. For instance, Novo A/S held 4.18% of Evotec's ADRs as of June 2024, valued at $54.3 million, while Mubadala Investment Company PJSC held 1.29% as of December 2024, worth $16.8 million. Collectively, institutional investors accounted for 5.81% of Evotec's stock by late 2024. The increasing participation of U.S. record holders, who owned 18.75% of outstanding ordinary shares and ADSs as of December 31, 2024, further diversifies the ownership base. This evolution in Evotec's ownership structure, particularly the increased institutional backing and the strategic NASDAQ listing, has been instrumental in funding its pipeline development, global expansion, and focus on high-value market segments, as detailed in the Competitors Landscape of Evotec.

Key Evotec Shareholders

Understanding who owns Evotec is crucial for grasping its strategic trajectory and market position.

• Novo Holdings A/S is a significant stakeholder.
• Mubadala Investment Company is another major investor.
• Triton GP HoldCo SARL also holds a substantial stake.
• Institutional investors collectively own a notable percentage of Evotec's stock.

Evotec PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Evotec SE operates with a two-tier board system, featuring a Management Board for daily operations and a Supervisory Board for oversight. As of May 2025, Prof. Dr. Iris Löw-Friedrich chairs the Supervisory Board, with Roland Sackers as Vice Chairman. The board includes members like Camilla Macapili Languille, representing a significant shareholder.

Evotec SE adheres to a one-share-one-vote principle, meaning each share typically carries equal voting rights. Shareholders are obligated to report changes in their voting power to the company and the German Federal Financial Supervisory Authority (BaFin) when thresholds like 3% or 10% are met or crossed. As of July 30, 2025, the company had a total of 177,766,541 voting rights. While Mubadala Investment Company holds around 7% of Evotec SE's voting shares, it does not constitute a controlling stake according to the German Corporate Governance Code, as there is no controlling agreement or outright majority ownership. Recent reports from 2024-2025 do not indicate any significant proxy fights or activist campaigns influencing the company's strategic decisions.

Understanding Evotec's Ownership Structure

Evotec's ownership is characterized by a dispersed shareholder base with no single controlling entity. Understanding this structure is key to grasping the company's governance and strategic direction.

• Evotec operates under a German two-tier board system.
• Voting power follows a one-share-one-vote principle.
• Mubadala Investment Company is a significant shareholder but not a controlling one.
• Shareholder voting rights are subject to reporting thresholds.
• The company's Growth Strategy of Evotec is influenced by its diverse shareholder landscape.

Evotec Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Recent strategic shifts and leadership changes have reshaped Evotec's ownership landscape. The company is focusing on core scientific strengths and divesting non-core assets, signaling a move away from venture capital-like investments.

Evotec's strategic realignment in early 2025 involved significant portfolio adjustments, including the divestment of its clinical program EVT 201 and exiting equity stakes in partners, such as a €70 million holding in Recursion Pharmaceuticals. These actions, alongside a workforce reduction of 400 employees completed in Q1 2025 and an exit from the gene therapy sector, underscore a commitment to a more focused operational model. The company's revenue for fiscal 2024 reached €797.0 million, with projections for 2025 indicating growth between 5-10%. This strategic direction was further solidified when Halozyme Therapeutics retracted its €2 billion acquisition proposal in November 2024, indicating Evotec's intent to pursue its independent path. As of early 2025, institutional investors held a substantial portion of Evotec's shares, with 60 institutions collectively owning 15,322,931 shares, reflecting increasing institutional interest in the company's Revenue Streams & Business Model of Evotec.

Leadership Transition

Dr. Christian Wojczewski became CEO on July 1, 2024, and Aurélie Dalbiez joined as Chief People Officer on June 15, 2024. These appointments signal a new phase for Evotec's management.

Strategic Portfolio Adjustments

Evotec is reducing its asset portfolio by approximately 30% and exiting certain business areas. This includes divesting equity stakes and discontinuing specific clinical programs.

Financial Outlook

The company projects revenue growth of 5-10% for 2025, aiming for a revenue CAGR of 8-12% between 2024 and 2028. This demonstrates confidence in its revised strategy.

Institutional Ownership Trends

As of early 2025, institutional investors are significant stakeholders, holding over 15 million shares. This highlights a notable level of institutional backing for Evotec's operations.

Evotec Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔